Non-alcoholic steatohepatitis (NASH): why biopsy?

Comment

A McNair. Gut. 2002 Dec.

. 2002 Dec;51(6):898; author reply 898-9.

doi: 10.1136/gut.51.6.898.

No abstract available

Comment on

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?
Day CP. Day CP. Gut. 2002 May;50(5):585-8. doi: 10.1136/gut.50.5.585. Gut. 2002. PMID: 11950797 Free PMC article. Review.

1. Sherwood P, Lyburn I, Brown S, et al. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. BMJ 2001;322:276–8. - PMC - PubMed
1. Matteoni C, Younossi Z, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–19. - PubMed
1. Tobkes A, Nord H. Liver biopsy: review of methodology and complications. Dig Dis 1995;13:267–74. - PubMed
1. Sherwood P, Lyburn I, Brown S, et al. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. BMJ 2002;322:276–8. - PMC - PubMed
1. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989;111:473–8. - PubMed